Prognostic Value of Inflammation-Based Markers in Advanced or Metastatic Neuroendocrine Tumours

Background: The role of systemic inflammation–based markers remains uncertain in advanced or metastatic neuroendocrine tumours (NETS). Methods: Systemic inflammatory factors, such as levels of circulating white blood cells and other blood components, were combined to yield inflammation-based prognostic scores [high-sensitivity inflammation-based Glasgow prognostic score (hSGPS), neutrophil:lymphocyte ratio (NLR), platelet:lymphocyte ratio (PLR), high-sensitivity inflammation-based prognostic index (hSPI), and prognostic nutritional index (PNI)], whose individual values as prognostic markers were retrospectively determined. Univariate and multivariate analyses were used to examine the association of inflammatory markers with overall survival (OS). Results: The study included 135 patients. Univariate analysis revealed that elevated white blood cell count, elevated neutrophil count, low serum albumin, elevated high-sensitivity C-reactive protein, and elevated hSPI, hSGPS, and NLR scores were significantly associated with worse OS. Multivariate analyses demonstrated that, apart from pathology grade and original site of the tumour, elevated hSPI (p = 0.004) was an independent prognostic factor for worse OS. Conclusions: In the present study, elevated pretreatment hSPI was observed to be an independent predictor of shorter OS in patients with inoperable advanced or metastatic NET. The hSPI might thus provide additional guidance for therapeutic decision-making in such patients.